Apostolia-Maria Tsimberidou, MD, PhD
The use of targeted matched therapy more than doubled 3-year overall survival (OS) in patients with refractory cancers compared with those who received nonmatched therapy, according to results from the IMPACT trial.
Lead author Apostolia-Maria Tsimberidou, MD, PhD, professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, presented these results at the 2018 ASCO Annual Meeting. She said that findings from studies like IMPACT exploring precision medicine could play a major role in cancer care, especially for patients with rare or difficult-to-treat diseases.
... to read the full story